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The regeneration of damaged or
diseased human tissues using specific
lineage-directed precursors could
soon be possible. Pluripotent stem
cell lines from human embryos have
recently been established in vitro.
Applying specific differentiation
techniques developed for murine
embryonic stem (ES) cells result in
lineage-restricted cells that can
integrate into damaged tissues and
restore function. In addition to these
embryo-derived stem cells, several
reports have recently described the
generation of cells of one tissue type
from cells normally restricted to
another lineage. However, the
mechanisms directing this
transdifferentiation, and the means
by which these cells may be
expanded are not clear. Furthermore,
the control of such events in culture
has yet to be developed. For this
reason stem cells derived from
embryos are likely to prove to be the
most efficient route for tissue
replacement therapy. This review
outlines the embryological origins of
the pluripotent stem cell lines
derived from murine embryos and
compares some of their
characteristics with those of their
human counterparts.
Stem cells of the early mouse embryo
The embryos of many vertebrates
develop in a pattern that is dictated
by cytoplasmic determinants in the
egg. The mammalian embryo,
however, stands alone in its
impressive capacity to develop
normally after cell ablation or re-
location of cells during cleavage. For
example, at the 2-cell stage the
mouse embryo can be separated into
blastomeres that can each develop
into a perfectly normal animal. In
rabbits and sheep, blastomeres
isolated at the 8-cell stage can give
rise to normal individuals. Removal
of blastomeres from the 16-cell stage
mammalian embryo does not result
in loss of any specific structure, as
occurs for example after cell ablation
in frog embryos. This facility for
regulation has been exploited in
agricultural applications with cattle
and sheep to generate multiple
individuals with a desirable genotype
from a single embryo, simply by
separation of the blastomeres during
preimplantation stages. It has also
been invaluable in allowing biopsy in
humans for pre-gestational screening
of inherited diseases in in vitro
fertilisation programmes. 
This flexibility, or totipotency of
mammalian development is reduced
as the morula becomes a blastocyst
when the first tissue, the
trophectoderm, differentiates on the
outside of the embryo. The
trophectoderm will give rise solely to
structures involved in invasion of the
uterus and establishment of the
placenta. The remaining inside
population of cells — the inner cell
mass, ICM, or pluriblast — is initially
totipotent, and has the capacity to
regenerate the trophectoderm if the
outside differentiated layer is
removed. Gradually, this regenerative
property is lost, but the cells of the
ICM remain equivalent to one
another and have the capacity to
form all tissues of the foetus as well
as additional extraembryonic
structures. The ICM cells are now
defined as pluripotent. 
Just before implantation a second
differentiative event occurs in the
ICM, resulting in formation of the
primitive endoderm or hypoblast on
the surface lining the blastocyst
cavity. This tissue is involved in
formation of the parietal and visceral
yolk sacs that will surround the
foetus in utero. The remainder of the
ICM is now known as the primitive
ectoderm or epiblast. In the mouse
the epiblast does not retain the
ability to produce further hypoblast
cells, but this is not a universal
property of mammalian embryos, and
is not shared by the rat for example,
whose development is otherwise very
similar. 
At around the time of
implantation the epiblast is merely a
ball of cells, but within a few hours
the cells begin to organise into a cup-
shaped epithelium. This event is
thought to be controlled by signals
from the visceral endoderm, a
derivative of the primitive endoderm
that surrounds the epiblast.
Following implantation the epiblast
enters a period of rapid cell division
that persists during gastrulation. This
is a time of progressive
differentiation as cells of the epiblast
become allocated to specific fates,
depending upon whether they have
passed through the primitive streak
and the subsequent position they
come to occupy. Interestingly, during
the early stages of gastrulation
ablation of up to 80% of the
developing embryo does not prevent
relatively normal subsequent
development. By the end of
gastrulation all of the epiblast cells
have differentiated; only the
primordial germ cells, located in the
posterior region of the embryo retain
the potential for development into all
tissues under appropriate conditions. 
Harnessing pluripotency in culture
To understand the biology of
mammalian pluripotent cells and to
exploit their potential uses it is
desirable to be able to grow them in
culture and manipulate them
genetically. In the 1970s embryonal
carcinoma (EC) cells were derived
from teratocarcinomas generated by
transferring ICM cells or epiblasts to
a permissive site, such as the testis or
kidney of a host animal.
Teratocarcinomas consist of many
differentiated cells and a population
of stem cells that can induce a second
tumour if transferred to another host;
and can also proliferate in vitro. EC
cells were the first pluripotent
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mammalian stem cells that could be
propagated in culture. Lines have
been successfully obtained using
murine embryos undergoing
gastrulation. When integrated into a
host morula or blastocyst, derivatives
from EC cells can occasionally be
found in many tissues of the
resulting adult mouse. However, they
rarely, if ever, contribute to the
germline. 
The establishment of murine
embryonic stem (ES) cell lines was a
major breakthrough in the early 80s.
ES cells were derived directly in
culture from ICMs, either isolated
from the trophectoderm or as intact
blastocysts. They have become
invaluable becasue of their ability to
colonise all tissues including the
germline when aggregated with a
host preimplantation embryo.
Consequently, it is possible, using
transgenic and gene targeting
technology, to create mice bearing
specific mutations that may be used
for studies in gene function or as
models for disease. In spite of
persistent effort, however, in contrast
to EC cells, ES cells have not yet
been derived from postimplantation
embryos. It is possible that
epithelialisation of the epiblast may
somehow inhibit the pluripotent
population from overcoming its
programmed differentiation when
subjected to the culture conditions
established for derivation of ES cells
from blastocysts.
An important ingredient for ES
cell derivation and propagation is
leukaemia inhibitory factor (LIF).
LIF is produced by the fibroblasts
upon which ES cells are frequently
cultured, but it may also be added to
the culture medium in purified form.
LIF and related cytokines operate
via a receptor incorporating the cell
surface glycoprotein gp130 that
recruits the signal transducer and
activator of transcription STAT3.
Enforced activation of STAT3 in ES
cells allows stem cell self-renewal
even in the absence of cytokines,
showing that LIF family members
maintain pluripotency primarily
through this signal transduction
pathway. 
In addition to STAT3 activation,
expression of the transcription factor
Oct-4 is absolutely required for ES
cell self-renewal. Oct-4 expression is
restricted to pluripotent stem cells
in vivo and in vitro; pluripotent cells
not expressing Oct-4 are never seen.
Differentiation of ES cells is
associated with down regulation of
Oct-4. Targeted deletion of Oct-4
results in embryos composed entirely
of trophectoderm that can implant in
the uterus, but fail to develop any
further. In normal embryos
completion of gastrulation is
coincident with restriction of Oct-4
expression to the primordial germ
cells. Cells resembling ES cells have
been derived from the primordial
germ cells of mice. These embryonic
germ (EG) cells can contribute to all
tissues, including the germline of
chimaeras. 
Pluripotent stem cell lines from
human embryos
Cells resembling mouse ES cells
have now been derived from surplus
human embryos donated by
informed, consenting couples
following in vitro fertilisation
treatment. It is obviously not
possible to test the developmental
potential of human ES cells by their
contribution to chimaeras, but
derivatives of all three germ layers —
ectoderm, mesoderm and endoderm
— have been generated in teratomas
formed by injecting these cells into
severe combined immunodeficient
(SCID) mice. More specifically,
Figure 1
Representation of the progression through
mouse development indicating the means of
generating various pluripotent stem cell lines
from specific stages. Totipotent cells
(orange), pluripotent cells and germ cells
(red), trophoblast lineage (blue) and extra-
embryonic endoderm (yellow) are indicated.
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neural epithelium, embryonic
ganglia, stratified squamous
epithelium, hair, cartilage, bone,
smooth and striated muscle and gut
epithelium have been identified in
these tumours. Human ES cells have
been defined on the strength of the
following criteria: they are derived
from preimplantation embryos; they
undergo prolonged undifferentiated
proliferation; and they have a stable
developmental potential to form
derivatives of all three germ layers.
The human ES cells derived by
Thomson and colleagues exhibit a
high levels of telomerase activity,
which plays an important role in
replicative life span of such cells:
these cells have been maintained in
culture for over a year. Such cells
may prove to be invaluable for the
in vitro study of early human
development, which differs
significantly from that of the mouse,
as well as for pharmacological
purposes, such as identifying gene
targets for new drugs and testing
teratogenic or toxic agents. 
In order for them to be of use for
tissue replacement therapy it must
be possible to direct their
differentiation along specific
pathways to produce a pure
population of the desired lineage that
can be incorporated into the
damaged tissue and function as
normal. No contamination with
undifferentiated ES cells can be
tolerated because of the risk of
subsequent tumour formation.
Murine ES cells can be directed
along various pathways of
differentiation in culture by applying
specific protocols. For example,
neurons, glial cells, cardiac tissue,
cells of osteogenic and
haematopoietic lineages have been
generated in vitro by various research
groups. Primitive and mature neural
cells have been derived from human
ES cells, but so far there have been
no reports of any functional or
replacement studies with these cells. 
Differentiation of human ES
cells into other specific lineages has
yet to be demonstrated. Human ES
cells are reported to be more difficult
to grow in culture than mouse ES
cells. They apparently do not
respond well when they are
disaggregated into single cells or
grown at low density and they
become necrotic or differentiate if
removed from the fibroblast feeder
layer, even in the presence of LIF or
related cytokines. The factors
produced by the feeder cells
required for stem cell self-renewal in
human ES cells are still unknown.
Human ES cells also differ from
murine ES cells in the specific
markers that they express. However,
Oct-4, which appears to be a key
requirement for pluripotency, is
expressed in ES cells from both
species. 
Pluripotent cell lines have also
been established from primordial
germ cells dissected from aborted
human embryos. Interestingly, these
cells resemble mouse ES cells more
closely than do the human
blastocyst-derived cells, at least in
their responsiveness to LIF and the
ease with which they can be
passaged. So far nothing is known
about the methylation status of the
imprinted genes in human EG cells.
This may be a matter for concern,
since relaxation of imprinting of
specific genes has been associated
with several human malignancies.
Human EG cells have not yet been
tested for their ability to
differentiate along specific lineages
by injection into SCID mice, but by
growing them at high density in
culture differentiation can be
observed and markers for derivatives
of all three germ layers have been
identified. 
The ability to derive human ES
cells is a very important step towards
cell replacement therapy.
Demonstration of specific lineage-
directed differentiation will certainly
be achieved soon. By adapting the
technology developed for murine ES
cells, such as gene targeting, to
remove incompatible genes of the
histocompatibility complex, it may
be possible to overcome the
anticipated problems of immune
rejection when clinical trials begin.
ES cell lines have been derived from
murine blastocysts generated by
nuclear transfer into enucleated
oocytes. Applying this technique
using genetically matched nuclei
may provide an alternative way to
overcome immune rejection.
However, the implications of
developing such a technique using
human embryos will invoke fear of
the possibility of generating whole
beings It may be a long time before
the obvious advantages of using
nuclear transfer for cell replacement
therapy are allowed to emerge in
clinical practice. 
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